These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 31444923)

  • 1. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
    Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
    Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
    Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
    Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL; Kim EH; Jang HJ; Park JY; Shin D
    Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
    Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
    Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
    Wang L; Liu Y; Zhao TL; Li ZZ; He JY; Zhang BJ; Du HZ; Jiang JW; Yuan ST; Sun L
    Phytomedicine; 2019 Apr; 57():117-128. PubMed ID: 30668314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
    Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
    Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.
    Yoshikawa M; Tsuchihashi K; Ishimoto T; Yae T; Motohara T; Sugihara E; Onishi N; Masuko T; Yoshizawa K; Kawashiri S; Mukai M; Asoda S; Kawana H; Nakagawa T; Saya H; Nagano O
    Cancer Res; 2013 Mar; 73(6):1855-66. PubMed ID: 23319806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma.
    Wang Z; Tang S; Cai L; Wang Q; Pan D; Dong Y; Zhou H; Li J; Ji N; Zeng X; Zhou Y; Shen YQ; Chen Q
    Br J Cancer; 2024 May; 130(11):1744-1757. PubMed ID: 38582810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma.
    Lu H; Lu Y; Xie Y; Qiu S; Li X; Fan Z
    JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Redox regulation in cancer stem cells].
    Saya H
    Nihon Rinsho; 2015 May; 73(5):790-4. PubMed ID: 25985632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension.
    Isobe S; Kataoka M; Endo J; Moriyama H; Okazaki S; Tsuchihashi K; Katsumata Y; Yamamoto T; Shirakawa K; Yoshida N; Shimoda M; Chiba T; Masuko T; Hakamata Y; Kobayashi E; Saya H; Fukuda K; Sano M
    Am J Respir Cell Mol Biol; 2019 Sep; 61(3):367-379. PubMed ID: 30897333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.
    Thanee M; Loilome W; Techasen A; Sugihara E; Okazaki S; Abe S; Ueda S; Masuko T; Namwat N; Khuntikeo N; Titapun A; Pairojkul C; Saya H; Yongvanit P
    Cancer Sci; 2016 Jul; 107(7):991-1000. PubMed ID: 27176078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
    Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
    Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
    Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
    Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.
    Wada F; Koga H; Akiba J; Niizeki T; Iwamoto H; Ikezono Y; Nakamura T; Abe M; Masuda A; Sakaue T; Tanaka T; Kakuma T; Yano H; Torimura T
    Cancer Sci; 2018 Sep; 109(9):2801-2810. PubMed ID: 29981246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
    Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
    Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
    Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications.
    Ju HQ; Lu YX; Chen DL; Tian T; Mo HY; Wei XL; Liao JW; Wang F; Zeng ZL; Pelicano H; Aguilar M; Jia WH; Xu RH
    Theranostics; 2016; 6(8):1160-75. PubMed ID: 27279909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
    Roh JL; Kim EH; Jang H; Shin D
    Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.